This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B et al. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia 2013; 27: 226–232.
Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood 2012; 120: 1597–1600.
McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. New Engl J Med 2012; 366: 1770–1781.
Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. New Engl J Med 2012; 366: 1759–1769.
Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. New Engl J Medicine 2012; 366: 1782–1791.
Rajkumar SV . Second to none. Blood, [Comment] 2012; 120: 1537–1539.
Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011; 118: 4086–4092.
Roeker LE, Larson DR, Kyle RA, Kumar S, Dispenzieri A, Rajkumar SV . Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients. Leukemia 2013; 27: 1391–1393.
Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S et al. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood 2013; 121: 4753–4757.
Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012; 26: 1730–1741.
Fernandez C, Santos-Silva MC, Lopez A, Matarraz S, Jara-Acevedo M, Ciudad J et al. Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis. Leukemia 2013; 27: 2149–2156.
Matarraz S, Paiva B, Diez-Campelo M, Corral LL, Perez E, Mateos MV et al. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide? Haematologica 2012; 97: 1608–1611.
van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908–1975.
Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210–2221.
Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen M et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012; 26: 1986–2010.
Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989. Blood 2008; 111: 94–100.
This work was supported by Fundación Científica de la Asociación Española Contra el Cáncer (AECC), Consejería de Sanidad; Gerencia Regional de Salud de Castilla y León (SACYL), Spain (BIO/SA24/13); Fundación Samuel Solórzano Barruso (University of Salamanca, Spain); Black Swan Research Initiative Signature Project of the International Myeloma Foundation, North Hollywood, CA, United States of America; and Cooperative Cancer Research Thematic Network (RTICC): RD12/0036/0048, Instituto de Salud Carlos III-FEDER, Ministerio de Economia y Competitividad, Madrid, Spain.
The authors declare no conflict of interest.
About this article
Cite this article
Matarraz, S., Paiva, B., Díez-Campelo, M. et al. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations. Leukemia 28, 1747–1750 (2014). https://doi.org/10.1038/leu.2014.103